Document is current
Any future updates will be listed below
-
Authors
Ghezelayagh, Talayeh S.
Kohrn, Brendan F.
Fredrickson, Jeanne
Krimmel-Morrison, Jeffrey D.
Latorre-Esteves, Elena
Tee, Xin-Ray
Radke, Marc R.
Manhardt, Enna
Norquist, Barbara M.
Katz, Ronit
Swisher, Elizabeth M.
Risques, Rosa Ana https://orcid.org/0000-0002-0291-1858
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA009515)
- License Information
-
More Information
Article History
Received: 8 September 2023
Revised: 14 June 2024
Accepted: 17 June 2024
First Online: 25 June 2024
Competing interests
: RAR is a consultant and equity holder at TwinStrand Biosciences Inc. and an equity holder at NanoString Technologies Inc. RAR is named inventor on patents owned by the University of Washington and licensed to TwinStrand Biosciences Inc. RAR received research funding from a joined research grant with TwinStrand Biosciences Inc. and Ovartec GmbH.
: This research was approved by the Human Subjects Division at the University of Washington (Institutional Review Board numbers 2872 and 7385) and was carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
